Ibrutinib to Allogenic Stem Cell Transplant in a Case of Refractory Mantle Cell Lymphoma
- 265 Downloads
We thank all the members, staff of Rajiv Gandhi Cancer Institute and Research Centre, India for their contribution in the conduct of the study.
Compliance with Ethical Standards
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by our Institutional Review Board.
The informed consent was obtained from the individual participant included in the study.
- 4.Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R et al (2014) Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. Blood 124(21):4471Google Scholar
- 5.Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P et al (2014) Cell cycle reprogramming for PI3 K inhibition overrides relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4(9):1022–1035CrossRefPubMedPubMedCentralGoogle Scholar